Skip to main content
Premium Trial:

Request an Annual Quote

Sara Cunningham Hall, Mike Catelani, Linda Couto, Paul Pockros, Robert Lanford, Jonathan Coates, Ken Reed, Arthur Riggs, Stephen Edwards

Premium
Tacere Therapeutics, a newly founded RNAi-based drug developer, said this week that it has appointed former Benitec CEO Sara Cunningham Hall as its president and CEO.
 
Before working at Benitec, Cunningham Hall was founder and vice president of intellectual property and business development at Avocel, which was acquired by Benitec in 2004.
 
Tacere also said that former Benitec CFO Mike Catelani has been named senior vice president and CFO, and former Benitec Preclinical Director Linda Couto has been named vice president of research and development.
 
The company also announced its scientific advisory board, which includes Paul Pockros of the Scripps Clinic Research Consortium, Robert Lanford of the Southwest Foundation for Biomedical Research, and Jonathan Coates, CEO of Avexa. (See related story, this issue, for further details on Tacere.
 

 
Ken Reed, co-founder of Benitec, has accepted a two-year sabbatical at the City of Hope in Duarte, Calif.
 
According to Reed, he will be working as a visiting investigator with Arthur Riggs, director of the City of Hope’s Beckman Research Institute.
 
Before founding Benitec, Reed was director of the Queensland Agriculture Biotechnology Center. He holds a PhD and MS in biochemistry from Australian National University and a BS in biochemistry/chemistry from Melbourne University.
 

 
The US Environmental Protection Agency announced that it has hired Stephen Edwards as systems biologist within the National Health and Environmental Effects Research Laboratory in Research Triangle Park, NC.
 
Edwards most recently served as a senior research scientist and research fellow at Merck’s Rosetta Inpharmatics subsidiary.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.